{"id":"W4402364275","doi":"10.1007/s12325-024-02974-y","title":"Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Eli Lilly and Company","keywords":"Medicine; Atopic dermatitis; Placebo; Rheumatology; Dermatology; Internal medicine; Randomized controlled trial; Physical therapy; Double blind; Alternative medicine; Pathology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005985108,0.001622444,0.003723935,0.0005655605,0.0007118356,0.001503121,0.001149108,0.003178837,0.00461254],"category_scores_gemma":[0.00378837,0.000976689,0.003916187,0.0006210512,0.001143582,0.001611235,0.0005706101,0.003487107,0.0006401922],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000704006,"about_ca_system_score_gemma":0.001671115,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005826261,"about_ca_topic_score_gemma":0.002264211,"domain_scores_codex":[0.9981986,0.001067171,0.000168587,0.000242769,0.0001852813,0.0001376788],"domain_scores_gemma":[0.9975067,0.0008832813,0.0007489398,0.0001679265,0.00029114,0.000402175],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9501767,0.01205403,0.001253112,0.002653264,0.002388902,0.00005007981,0.0001315467,0.0002377643,0.005745485,0.0001233171,0.001188237,0.02399765],"study_design_scores_gemma":[0.9412283,0.05480732,0.001783502,0.00008911165,0.0008006866,0.00003403195,0.00002091817,0.0001630265,0.0004204526,0.00008106028,0.0005570846,0.00001451866],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9579178,0.02108829,0.001990043,0.001684004,0.0008261708,0.01107809,0.002425118,0.0002937555,0.00269667],"genre_scores_gemma":[0.9540282,0.01195829,0.006989084,0.002451272,0.0009649153,0.01875285,0.001779429,0.00005303296,0.003022942],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005985108,"threshold_uncertainty_score":0.03165269,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03107844180460009,"score_gpt":0.3778267599319135,"score_spread":0.3467483181273134,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}